Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries

U. Zeymer, P. Widimsky, N. Danchin, M. Lettino, A. Bardaji, JA. Barrabes, A. Cequier, MJ. Claeys, L. De Luca, J. Dörler, D. Erlinge, P. Erne, P. Goldstein, SM. Koul, G. Lemesle, TF. Lüscher, CM. Matter, G. Montalescot, D. Radovanovic, JL. Sendón,...

. 2016 ; 2 (4) : 229-43. [pub] 20160302

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011059

AIMS: Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60-70% of patients admitted with acute coronary syndromes in clinical practice. This study provides a 'real-life' overview of NSTE-ACS patient characteristics, dual antiplatelet therapy clinical practice, and outcomes at both the time of discharge from hospital and up to 1-year post-discharge. METHODS AND RESULTS: A total of 10 registries (documenting 84 054 NSTE-ACS patients) provided data in a systematic manner on patient characteristics and outcomes for NSTE-ACS in general, and 6 of these (with 52 173 NSTE-ACS patients) also provided more specific data according to P2Y12 receptor inhibitor used. Unadjusted analyses were performed at the study level, and no formal meta-analysis was performed due to large heterogeneity between studies in the settings, patient characteristics, and outcome definitions. All-cause death rates across registries ranged from 0.76 to 4.79% in-hospital, from 1.61 to 6.65% at 30 days, from 3.66 to 7.16% at 180 days, and from 3.14 to 9.73% at 1 year. Major bleeding events were reported in up to 2.77% of patients while in hospital (in seven registries), up to 1.08% at 30 days (data from one registry only), and 2.06% at 1 year (one registry). CONCLUSIONS: There were substantial differences in the use of and patient selection for clopidogrel, prasugrel, and ticagrelor, which were associated with differences in short- and long-term ischaemic and bleeding events. In future registries, data collection should be performed in a more standardized way with respect to endpoints, definitions, and time points.

2nd Department of Medicine with Cardiology and Intensive Care Hospital Rudolfstiftung Vienna Austria

AMIS Plus Data Center Epidemiology Biostatistics and Prevention Institute University of Zurich Zurich Switzerland

AMIS Plus Data Center University of Zurich Zurich Switzerland

Cardiac Intensive Care Unit Interventional Cardiology Hopital Cardiologique Centre Hospitalier Régional et Universitaire de Lille Lille France

Cardiocenter 3rd Faculty of Medicine Charles University Prague Czech Republic

Cardiology Department Hospital La Paz IdiPaz Madrid Spain

Cardiology Department University Heart Center University Hospital Zurich University of Zurich Zurich Switzerland

Cardiology Freeman Hospital and Institute of Cellular Medicine Newcastle upon Tyne UK

Cardiology Service Hospital Universitari de Tarragona Joan XXIII IISPV Tarragona Spain

Cardiology Service Hospital Universitari Vall d'Hebron Barcelona Spain

Cardiology Unit Humanitas Research Hospital Rozzano Milano Italy

Department of Cardiology Hospital Européen Georges Pompidou and Université Paris Descartes Paris France

Department of Cardiology Leiden University Medical Center Leiden The Netherlands

Department of Cardiology Lund University Skåne University Hospital Lund Lund Sweden

Department of Cardiology University Hospital Antwerp Edegem Belgium

Department of Cardiovascular Sciences Laboratory of Interventional Cardiology European Hospital Rome Italy

Heart Disease Institute Bellvitge University Hospital IDIBELL University of Barcelona Barcelona Spain

Klinikum Ludwigshafen and Institut für Herzinfarktforschung Ludwigshafen Bremser Str 79 D 67063 Ludwigshafen Germany

Pôle de l'urgence Service de SAMU du Nord Centre Hospitalier régional Universitaire de Lille Lille France

Swansea University Medical School Swansea Wales UK

Université Paris 06 ACTION Study Group INSERM UMRS 1166 Institut de Cardiologie Pitié Salpêtrière University Hospital Paris France

University Clinic of Internal Medicine 3 Cardiology and Angiology Medical University of Innsbruck Innsbruck Austria

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011059
003      
CZ-PrNML
005      
20180426112014.0
007      
ta
008      
180404s2016 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ehjcvp/pvw005 $2 doi
035    __
$a (PubMed)27533946
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Zeymer, Uwe $u Klinikum Ludwigshafen and Institut für Herzinfarktforschung Ludwigshafen, Bremser Str. 79, D-67063 Ludwigshafen, Germany uwe.zeymer@t-online.de.
245    10
$a P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries / $c U. Zeymer, P. Widimsky, N. Danchin, M. Lettino, A. Bardaji, JA. Barrabes, A. Cequier, MJ. Claeys, L. De Luca, J. Dörler, D. Erlinge, P. Erne, P. Goldstein, SM. Koul, G. Lemesle, TF. Lüscher, CM. Matter, G. Montalescot, D. Radovanovic, JL. Sendón, P. Tousek, F. Weidinger, CF. Weston, A. Zaman, P. Andell, J. Li, JW. Jukema, . ,
520    9_
$a AIMS: Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60-70% of patients admitted with acute coronary syndromes in clinical practice. This study provides a 'real-life' overview of NSTE-ACS patient characteristics, dual antiplatelet therapy clinical practice, and outcomes at both the time of discharge from hospital and up to 1-year post-discharge. METHODS AND RESULTS: A total of 10 registries (documenting 84 054 NSTE-ACS patients) provided data in a systematic manner on patient characteristics and outcomes for NSTE-ACS in general, and 6 of these (with 52 173 NSTE-ACS patients) also provided more specific data according to P2Y12 receptor inhibitor used. Unadjusted analyses were performed at the study level, and no formal meta-analysis was performed due to large heterogeneity between studies in the settings, patient characteristics, and outcome definitions. All-cause death rates across registries ranged from 0.76 to 4.79% in-hospital, from 1.61 to 6.65% at 30 days, from 3.66 to 7.16% at 180 days, and from 3.14 to 9.73% at 1 year. Major bleeding events were reported in up to 2.77% of patients while in hospital (in seven registries), up to 1.08% at 30 days (data from one registry only), and 2.06% at 1 year (one registry). CONCLUSIONS: There were substantial differences in the use of and patient selection for clopidogrel, prasugrel, and ticagrelor, which were associated with differences in short- and long-term ischaemic and bleeding events. In future registries, data collection should be performed in a more standardized way with respect to endpoints, definitions, and time points.
650    _2
$a akutní koronární syndrom $x farmakoterapie $x mortalita $7 D054058
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a Evropa $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x chemicky indukované $x epidemiologie $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a ischemie $x etiologie $x prevence a kontrola $7 D007511
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výběr pacientů $7 D018579
650    _2
$a inhibitory agregace trombocytů $x škodlivé účinky $x terapeutické užití $7 D010975
650    _2
$a antagonisté purinergních receptorů P2Y $x škodlivé účinky $x terapeutické užití $7 D058921
650    12
$a purinergní receptory P2Y12 $7 D058925
650    _2
$a registrace $7 D012042
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Widimsky, Petr $u Cardiocenter, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Danchin, Nicolas $u Department of Cardiology, Hospital Européen Georges Pompidou and Université Paris Descartes, Paris, France.
700    1_
$a Lettino, Maddalena $u Cardiology Unit, Humanitas Research Hospital, Rozzano, Milano, Italy.
700    1_
$a Bardaji, Alfredo $u Cardiology Service, Hospital Universitari de Tarragona Joan XXIII, IISPV, Tarragona, Spain.
700    1_
$a Barrabes, Jose A $u Cardiology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
700    1_
$a Cequier, Angel $u Heart Disease Institute, Bellvitge University Hospital IDIBELL, University of Barcelona, Barcelona, Spain.
700    1_
$a Claeys, Marc J $u Department of Cardiology, University Hospital Antwerp, Edegem, Belgium.
700    1_
$a De Luca, Leonardo $u Department of Cardiovascular Sciences, Laboratory of Interventional Cardiology European Hospital, Rome, Italy.
700    1_
$a Dörler, Jakob $u University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.
700    1_
$a Erlinge, David $u Department of Cardiology, Lund University, Skåne University Hospital Lund, Lund, Sweden.
700    1_
$a Erne, Paul $u AMIS Plus Data Center, University of Zurich, Zurich, Switzerland.
700    1_
$a Goldstein, Patrick $u Pôle de l'urgence, Service de SAMU du Nord, Centre Hospitalier régional Universitaire de Lille, Lille, France.
700    1_
$a Koul, Sasha M $u Department of Cardiology, Lund University, Skåne University Hospital Lund, Lund, Sweden.
700    1_
$a Lemesle, Gilles $u Cardiac Intensive Care Unit, Interventional Cardiology Hopital Cardiologique, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.
700    1_
$a Lüscher, Thomas F $u Cardiology Department, University Heart Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
700    1_
$a Matter, Christian M $u Cardiology Department, University Heart Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
700    1_
$a Montalescot, Gilles $u Université Paris 06, ACTION Study Group, INSERM-UMRS 1166, Institut de Cardiologie, Pitié-Salpêtrière University Hospital (AP-HP), Paris, France.
700    1_
$a Radovanovic, Dragana $u AMIS Plus Data Center, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
700    1_
$a Sendón, Jose Lopez $u Cardiology Department, Hospital La Paz. IdiPaz, Madrid, Spain.
700    1_
$a Tousek, Petr $u Cardiocenter, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Weidinger, Franz $u Second Department of Medicine with Cardiology and Intensive Care, Hospital Rudolfstiftung, Vienna, Austria.
700    1_
$a Weston, Clive F M $u Swansea University, Medical School, Swansea, Wales, UK.
700    1_
$a Zaman, Azfar $u Cardiology, Freeman Hospital and Institute of Cellular Medicine, Newcastle upon Tyne, UK.
700    1_
$a Andell, Pontus $u Department of Cardiology, Lund University, Skåne University Hospital Lund, Lund, Sweden.
700    1_
$a Li, Jin $u Cardiology Department, University Heart Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
700    1_
$a Jukema, J Wouter $u Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
700    1_
$a ,
773    0_
$w MED00195025 $t European heart journal. Cardiovascular pharmacotherapy $x 2055-6845 $g Roč. 2, č. 4 (2016), s. 229-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27533946 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180426112124 $b ABA008
999    __
$a ok $b bmc $g 1288544 $s 1007871
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 2 $c 4 $d 229-43 $e 20160302 $i 2055-6845 $m European heart journal. Cardiovascular pharmacotherapy $n Eur Heart J Cardiovasc Pharmacother $x MED00195025
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace